Delving into the Latest Updates on [68Ga]-DOTA-IBA with Synapse

Overview

Basic Info

Drug Type

Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC)

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Bone metastases

Inactive Indication-

Originator Organization

Southwest Medical University

Active Organization

Southwest Medical University

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

AbstractA 29-year-old man with Ewing sarcoma in the right ankle underwent 68Ga-DOTA-IBA PET/CT and 18F-FDG PET/CT, both of which showed high radiotracer activity for the primary tumor. Interestingly, bone metastases were detected early using 68Ga-DOTA-IBA PET/CT for the sixth thoracic vertebrae and with 18F-FDG PET/CT for the bilateral humerus. Higher uptake of 68Ga-DOTA-IBA was found in both primary and metastatic sites of Ewing sarcoma. 177Lu-DOTA-IBA may be one of the possible therapies for metastatic or recurrent Ewing sarcoma.

01 Nov 2024·Clinical Nuclear Medicine

Increased Uptake of 68Ga-DOTA-IBA in Multiple Subcutaneous Metastases of Prostate Cancer

Article

Author: Shang, Xiaoyan ; Chen, Yue ; Wang, Wei ; Liu, Huipan ; Liu, Yuhong

AbstractSubcutaneous metastases are rare in prostate cancer. Herein, we present a case of a 66-year-old man with prostate cancer, who underwent 68Ga-labeled DOTA-ibandronic acid (68Ga-DOTA-IBA) PET/CT to explore the possibility of 177Lu-DOTA-IBA treatment. 68Ga-DOTA-IBA PET/CT demonstrated intensely increased uptake in the multiple osteoblastic bone metastases. Unexpectedly, 68Ga-DOTA-IBA uptake in multiple subcutaneous metastases was also noted.

100 Deals associated with [68Ga]-DOTA-IBA

Login to view more data